Periplocin Alleviates Cardiac Remodeling in DOCA-Salt-Induced Heart Failure Rats.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a common public health problem associated with increased morbidity and long-term mortality. However, effective treatment for HFpEF was not discovered yet. In the present study, we aimed to decipher the effects of Periplocin on DOCA-induced heart failure rats and explore the possible underlying mechanisms. We demonstrated that Periplocin could significantly attenuate cardiac structural remodeling and improve cardiac diastolic function. Of note, Periplocin significantly inhibited the recruitment of inflammatory and immune cells and decreased the expression of serum inflammatory cytokines. Meanwhile, Periplocin had the effect of cardiac glycosides to improve cardiomyocyte contractility and calcium transient amplitude. These findings indicate that Periplocin might be a potential medicine to treat HFpEF in patients.

• Authors: Jiameng Hao, Liping Chang, Dandong Wang, Chuanyuan Ji, Shaolan Zhang, Yunlong Hou, Yiling Wu
• Journal: Journal of cardiovascular translational research (J Cardiovasc Transl Res) Vol. 16 Issue 1 Pg. 127-140 (02 2023) ISSN: 1937-5395 [Electronic] United States
• PMID: 35616880 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• periplocin
• Desoxycorticosterone Acetate

Topics

• Rats
• Animals
• Desoxycorticosterone Acetate
• Ventricular Remodeling
• Stroke Volume
• Heart Failure
• Myocytes, Cardiac (metabolism)